<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946162</url>
  </required_header>
  <id_info>
    <org_study_id>20-63mrx</org_study_id>
    <nct_id>NCT04946162</nct_id>
  </id_info>
  <brief_title>The Use of Tadalafil in Confirmed COVID-19 Pneumonia.</brief_title>
  <official_title>The Use of Tadalafil in Confirmed COVID-19 Pneumonia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santa Barbara Cottage Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santa Barbara Cottage Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to assess the effects of Tadalafil in the setting of confirmed COVID-19&#xD;
      pneumonia. In particular we plan to assess its effects on oxygen saturation, P:F ratio, and&#xD;
      mixed central venous oxygen&#xD;
&#xD;
      We plan to recruit all hospitalized patients at Santa Barbara Cottage Hospital with a&#xD;
      confirmed COVID19 pneumonia (positive PCR + clinical signs/symptoms of lower respiratory&#xD;
      disease) who meet the Berlin definition of ARDS and have access to measure a mixed venous&#xD;
      oxygen saturation. For the purposes of obtaining mixed central venous oxygen, all&#xD;
      participating patients will already have an internal jugular central venous catheter in place&#xD;
      for inclusion in this study. Since all patients will be intubated, their Legally Authorized&#xD;
      Representative (LAR) will be approached to discuss the study and asked to participate in the&#xD;
      study by an ICU physician, either the attending physician or a medical resident.&#xD;
&#xD;
      Informed consent will be obtained from the LAR by an ICU attending physician or resident&#xD;
      involved in the study prior to participation. Patients who meet the above eligibility&#xD;
      criteria will have baseline levels of mixed central venous oxygen, oxygen saturation, P:F&#xD;
      ratio, blood pressure and PaO2 recorded.&#xD;
&#xD;
      Each patient will then receive Tadalafil 40mg once. The above listed parameters will be&#xD;
      monitored again 30 minutes after drug administration and 4 hours after drug administration.&#xD;
      No other medication or ventilator changes will be made during this time period outside of&#xD;
      emergent changes in the setting of patient deterioration. We will continue to analyze the&#xD;
      data in the event of emergent ventilator changes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The investigators never completed the IRB application due to decrease in need to conduct the&#xD;
    study.&#xD;
  </why_stopped>
  <start_date type="Actual">April 20, 2020</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">April 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will serve as a self-control, with values recorded pre-medication, 30 minutes after medication administration, and 4 hours after administration.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in P:F ratio</measure>
    <time_frame>Pre-medication, 30 minutes post medication, 4 hours post-medication</time_frame>
    <description>Change in a patient's P:F ratio after medication administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in oxygen saturation</measure>
    <time_frame>Pre-medication, 30 minutes post medication, 4 hours post-medication</time_frame>
    <description>Change in oxyhemoglobin as noted on an arterial blood gas sample after medication administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in partial pressure of oxygen in the bloodstream</measure>
    <time_frame>Pre-medication, 30 minutes post medication, 4 hours post-medication</time_frame>
    <description>Change in oxygen partial pressure (aka PaO2) as noted on an arterial blood gas sample after medication administration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID</condition>
  <condition>Sars-CoV2</condition>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>Tadalafil Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will be given tadalafil 40 mg one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil Pill</intervention_name>
    <description>Each patient will be given tadalafil 40 mg one time</description>
    <arm_group_label>Tadalafil Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patients at SBCH with confirmed COVID19 pneumonia (PCR + clinical&#xD;
             signs/symptoms of lower respiratory disease)&#xD;
&#xD;
          -  Patients currently on a ventilator&#xD;
&#xD;
          -  Patients who meet the Berlin definition of ARDS&#xD;
&#xD;
          -  Patients who have access to measure a mixed venous oxygen saturation (i.e., patients&#xD;
             with an internal jugular central venous catheter)&#xD;
&#xD;
          -  Patient and/or Legally Authorized Representative is willing/able to provide informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As tadalafil is currently a FDA Class B1 medication, indicating that little&#xD;
             information is available, pregnant women along with women who are actively&#xD;
             breastfeeding will be excluded from this series.&#xD;
&#xD;
          -  All patients under 18&#xD;
&#xD;
          -  Patients who are routinely taking nitrate medications&#xD;
&#xD;
          -  All patients using Tadalafil daily for pulmonary arterial hypertension (Note: patients&#xD;
             using Tadalafil intermittently for erectile dysfunction may still participate in the&#xD;
             study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>https://www.globenewswire.com/news-release/2020/03/25/2006042/0/en/Nu-Med-Plus-Closely-Monitoring-Outcomes-on-Two-New-Human-Clinical-Trials-Using-Inhaled-Nitric-Oxide-in-Treatment-of-COVID-19.html</url>
    <description>Nu-Med Plus Closely Monitoring Outcomes on Two New Human Clinical Trials Using Inhaled Nitric Oxide in Treatment of COVID-19</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT04304313</url>
    <description>A Pilot Study of Sildenafil in COVID-19</description>
  </link>
  <reference>
    <citation>Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30.</citation>
    <PMID>32381264</PMID>
  </reference>
  <reference>
    <citation>Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020 Jun;220:1-13. doi: 10.1016/j.trsl.2020.04.007. Epub 2020 Apr 15.</citation>
    <PMID>32299776</PMID>
  </reference>
  <reference>
    <citation>Keyaerts E, Vijgen L, Chen L, Maes P, Hedenstierna G, Van Ranst M. Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound. Int J Infect Dis. 2004 Jul;8(4):223-6.</citation>
    <PMID>15234326</PMID>
  </reference>
  <reference>
    <citation>Akerström S, Mousavi-Jazi M, Klingström J, Leijon M, Lundkvist A, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb;79(3):1966-9.</citation>
    <PMID>15650225</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Erratum in: Circulation. 2011 Sep 6;124(10):e279. Dosage error in article text.</citation>
    <PMID>19470885</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

